Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers and liver inflammation measures in patients with obesity and cardiovascular risk factors. The company said hsCRP levels fell markedly and multiple secondary biomarkers moved favorably; safety and tolerability were consistent with expectations. Investors reacted positively and the stock jumped after the readout as analysts framed the results as validation of the NLRP3 target for cardiometabolic disease.